

Curriculum Vitae

Personal information **David Khan**

Work experience

1. Employer: Medical Products Agency
 - Start date: 042016
 - End date:
 - Position: Pharmacokinetic assessor / pharmacometician
 - Activities:
 - Country: Sweden

Education and training

1. Subject: Uppsala University
 - Start date: 062009
 - End date: 082010
 - Qualification: Research summer school (SOFOSKO)
 - Organisation: Pharmacokinetics and mechanism_based PKPD modeling.
 - Country: Sweden
2. Subject: Pharmacometrics group, Department of Pharmaceutical Biosciences, Uppsala University
 - Start date: 122010
 - End date: 052016
 - Qualification: PhD
 - Organisation: PKPD modeling of antibiotics
 - Country: Sweden
3. Subject: Uppsala University
 - Start date: 012006
 - End date: 092010
 - Qualification: Master of Pharmaceutical Sciences
 - Organisation: Pharmacy, Pharmacokinetics, Pharmaceutical Sciences, Chemistry, Physiology, Pharmacometrics
 - Country: Sweden

Additional information

Publications

Khan DD, Lagerbäck P, Malmberg C, Kristoffersson AN, Wistrand-Yuen E, Sha C, Cars O, Andersson DI, Hughes D, Nielsen EI, Friberg LE. Predicting mutant selection in competition experiments with ciprofloxacin-exposed *Escherichia coli*. *Int J Antimicrob Agents*. 2018 Mar;51(3):399-406. doi: 10.1016/j.ijantimicag.2017.10.019. Epub 2017 Nov 7. PMID: 29127049

Nielsen EI, **Khan DD**, Cao S, Lustig U, Hughes D, Andersson DI, Friberg LE. Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. *J Antimicrob Chemother*. 2017 Nov 1;72(11):3108-3116. doi: 10.1093/jac/dkx269. PMID: 28961946

Khan DD, Friberg LE, Nielsen EI. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin. *J Antimicrob Chemother*. 2016 Jul;71(7):1881-4

Khan DD, Lagerbäck P, Cao S, Lustig U, Nielsen EI, Cars O, Hughes D, Andersson DI, Friberg LE. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. *J Antimicrob Chemother*. 2015 Nov;70(11):3051-60

Karres D, Pino-Barrio MJ, Benchetrit S, Benda N, Cochat P, Galluzzo S, García-Solís A, Gonzalez S, de Lisa R, **Khan D**, Lankester R, Lentz F, Martínez-Ortega PA, Montilla S, Morales DR, Tshinanu FM, Sánchez SP, Montero AR, Scherer S, Thomson A, Garrido BT, Umuhire D, Wang S, Bax R, Hedberg N. Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation. *Br J Pharmacol*. 2025 Feb;182(3):484-494.

Projects

Memberships

Other Relevant Information